No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KPTI Karyopharm Therapeutics
- 1.155
- -0.065-5.33%
Close Apr 15 16:00 ET
132.90MMarket Cap-924P/E (TTM)
1.225High1.140Low810.68KVolume1.220Open1.220Pre Close952.47KTurnover0.77%Turnover RatioLossP/E (Static)115.07MShares4.11052wk High-0.98P/B121.46MFloat Cap0.61752wk Low--Dividend TTM105.16MShs Float49.005Historical High--Div YieldTTM6.97%Amplitude0.617Historical Low1.174Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Onco360 Selected As The Preferred National Specialty Pharmacy Partner For Karyopharm's Product XPOVIO, A First-In-Class, XPO-1 Inhibitor
Onco360, the nation's largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm's product XPOVIO (selinexor), a first-in-class, XPO-1 inhibitor. XPOV
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)
Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
Barclays Gives a Buy Rating to Karyopharm Therapeutics (KPTI)
Comments
Analysts hold mixed views on Karyopharm Therapeutics due to its slower growth compared to the industry and increased loss per share estimates for next year, leading to a lower future valuation estimate.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported And Analysts Have Been Cutting Their Estimates
$Karyopharm Therapeutics(KPTI.US$ They state good sales and cash runway to 2025, with buyout potential. In at 1.70
1
$Karyopharm Therapeutics(KPTI.US$ Interesting..
1
Investors' belief in Karyopharm Therapeutics' poor revenue performance and underwhelming outlook contribute to its low P/S ratio. These conditions form a barrier for the share price.
2
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg